Who are immediate Cervarix, delayed MenVeo vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluad and Prevenar13, Healive+Havrix, COVAX+IIV4; COVAX+PPV23, MMR followed by YF, Prevenar 13 + Pneumovax 23, HyperAcute-Pancreas Immunotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/immediate-cervarix-delayed-menveo-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

immediate Cervarix, delayed MenVeo vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

immediate Cervarix, delayed MenVeo vaccine (immediate Cervarix, delayed MenVeo vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine combination. Area: Immunology / Infectious Disease Prevention.

marketed vaccine combination Immunology / Infectious Disease Prevention Biologic Live · refreshed every 30 min

Target snapshot

immediate Cervarix, delayed MenVeo vaccine (immediate Cervarix, delayed MenVeo vaccine) — Massachusetts General Hospital. This is a vaccination regimen combining two separate vaccines: Cervarix (HPV vaccine) given immediately and Menhibrix or Menveo (meningococcal vaccine) given on a delayed schedule to provide protection against human papillomavirus and meningococcal disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
immediate Cervarix, delayed MenVeo vaccine TARGET	immediate Cervarix, delayed MenVeo vaccine	Massachusetts General Hospital	marketed	vaccine combination
Fluad and Prevenar13	Fluad and Prevenar13	Korea University Guro Hospital	marketed	vaccine combination
Healive+Havrix	Healive+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine combination
COVAX+IIV4; COVAX+PPV23	COVAX+IIV4; COVAX+PPV23	China National Biotec Group Company Limited	marketed	vaccine combination
MMR followed by YF	MMR followed by YF	Alba Maria Ropero	marketed	Live attenuated viral vaccine combination
Prevenar 13 + Pneumovax 23	Prevenar 13 + Pneumovax 23	Poitiers University Hospital	marketed	Pneumococcal vaccine combination
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine combination class)

China National Biotec Group Company Limited · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). immediate Cervarix, delayed MenVeo vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/immediate-cervarix-delayed-menveo-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab